ZIOPHARM Oncology, Inc, a biotechnology company, focuses on acquiring, developing, and commercializing a portfolio of immuno-oncology therapies for treating heterogenous solid tumors and unknown antigens. The company develops two immuno-oncology platform technologies, including Sleeping Beauty (SB), which is based on the genetic engineering of immune cells using a non-viral transposon/transposase system to reprogram T-cells outside of the body for infusion; and Controlled IL-12, which delivers interleukin 12 or IL-12, a master regular of the immune system, in a controlled and safe manner to focus the patient's immune system to attack cancer cells.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Phone617-259-1970
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$150,000.00
Profitability
Miscellaneous
Employees48
Next Earnings Date11/8/2019 (Estimated)
OptionableOptionable
ZIOPHARM Oncology (NASDAQ:ZIOP) Frequently Asked Questions
What is ZIOPHARM Oncology's stock symbol?
ZIOPHARM Oncology trades on the NASDAQ under the ticker symbol "ZIOP."
How were ZIOPHARM Oncology's earnings last quarter?
ZIOPHARM Oncology Inc. (NASDAQ:ZIOP) issued its earnings results on Thursday, August, 8th. The biotechnology company reported ($0.09) EPS for the quarter, missing the Zacks' consensus estimate of ($0.08) by $0.01. During the same quarter last year, the firm earned ($0.12) EPS. View ZIOPHARM Oncology's Earnings History.
When is ZIOPHARM Oncology's next earnings date?
What price target have analysts set for ZIOP?
4 brokers have issued 1-year target prices for ZIOPHARM Oncology's stock. Their forecasts range from $5.50 to $7.50. On average, they expect ZIOPHARM Oncology's share price to reach $6.6250 in the next twelve months. This suggests a possible upside of 44.3% from the stock's current price. View Analyst Price Targets for ZIOPHARM Oncology.
What is the consensus analysts' recommendation for ZIOPHARM Oncology?
4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ZIOPHARM Oncology in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for ZIOPHARM Oncology.
What are Wall Street analysts saying about ZIOPHARM Oncology stock?
Here are some recent quotes from research analysts about ZIOPHARM Oncology stock:
- 1. According to Zacks Investment Research, "ZIOPHARM Oncology, Inc. is a biopharmaceutical company engaged in the development and commercialization of a diverse, risk-sensitive portfolio of in-licensed cancer drugs to address unmet medical needs. The Company applies new insights from molecular and cancer biology to understand the efficacy and safety limitations of approved and developmental cancer therapies and identifies proprietary and related molecules for better patient treatment. " (9/8/2019)
- 2. HC Wainwright analysts commented, "We have updated our model to reflect the reported 1Q19 financial results, and we project revenues of $3.2M and a net loss of $0.33 per share for 2019. The company reported cash and cash equivalents of $51.5M at the end of 1Q19, which we believe is sufficient to maintain operations until 2Q20. Clinical updates on controlled IL-12 at ASCO. Management announced that two clinical updates on its controlled IL-12 program (Ad-RTS-hIL-12 plus veledimex) for the treatment of recurrent GBM (rGBM) are expected to be presented at the 2019 Oncology (ASCO) Annual Meeting in June. Recall, Ziopharm is conducting two Phase 1 studies to evaluate the IL-12 platform as a monotherapy or as combination therapy with nivolumab (marketed by Bristol-Myers Squibb (BMY; not rated) as Opdivo)." (5/9/2019)
Has ZIOPHARM Oncology been receiving favorable news coverage?
Media stories about ZIOP stock have been trending negative this week, InfoTrie reports. The research group ranks the sentiment of press coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. ZIOPHARM Oncology earned a media sentiment score of -2.9 on InfoTrie's scale. They also gave media coverage about the biotechnology company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an impact on the company's share price in the next few days. View News Stories for ZIOPHARM Oncology.
Are investors shorting ZIOPHARM Oncology?
ZIOPHARM Oncology saw a increase in short interest in August. As of August 31st, there was short interest totalling 46,015,400 shares, an increase of 5.5% from the July 31st total of 43,634,300 shares. Based on an average daily volume of 2,150,000 shares, the short-interest ratio is presently 21.4 days. Currently, 29.2% of the shares of the stock are sold short. View ZIOPHARM Oncology's Current Options Chain.
Who are some of ZIOPHARM Oncology's key competitors?
Some companies that are related to ZIOPHARM Oncology include BridgeBio Pharma (BBIO), Arrowhead Pharmaceuticals (ARWR), HUTCHISON CHINA/S (HCM), Emergent Biosolutions (EBS), Reata Pharmaceuticals (RETA), Genmab A/S (GMAB), Ultragenyx Pharmaceutical (RARE), Arena Pharmaceuticals (ARNA), PTC Therapeutics (PTCT), Biohaven Pharmaceutical (BHVN), Amicus Therapeutics (FOLD), Myokardia (MYOK), Intercept Pharmaceuticals (ICPT), Agios Pharmaceuticals (AGIO) and Portola Pharmaceuticals (PTLA).
What other stocks do shareholders of ZIOPHARM Oncology own?
Who are ZIOPHARM Oncology's key executives?
ZIOPHARM Oncology's management team includes the folowing people:
- Dr. Laurence James Neil Cooper, CEO & Director (Age 54)
- Dr. David M. Mauney M.D., Pres (Age 50)
- Mr. Kevin G. Lafond, Sr. VP of Fin., Chief Accounting Officer & Treasurer (Age 63)
- Ms. Lynn M. Ferrucci PHR, Sr. VP of HR, Facilities, IT & Admin.
- Mr. David Connolly, VP of Corp. Communications & Investor Relations
Who are ZIOPHARM Oncology's major shareholders?
ZIOPHARM Oncology's stock is owned by a variety of of retail and institutional investors. Top institutional investors include BlackRock Inc. (7.23%), Vanguard Group Inc. (6.92%), Northern Trust Corp (1.06%), Morgan Stanley (0.85%), Charles Schwab Investment Management Inc. (0.56%) and Nuveen Asset Management LLC (0.43%). Company insiders that own ZIOPHARM Oncology stock include David M Md Mauney and Laurence James Neil Cooper. View Institutional Ownership Trends for ZIOPHARM Oncology.
Which major investors are selling ZIOPHARM Oncology stock?
ZIOP stock was sold by a variety of institutional investors in the last quarter, including Bank of America Corp DE, Ibex Investors LLC, Virtus ETF Advisers LLC, Mitsubishi UFJ Kokusai Asset Management Co. Ltd., HighTower Advisors LLC, BNP Paribas Arbitrage SA, UBS Asset Management Americas Inc. and Oppenheimer & Co. Inc.. View Insider Buying and Selling for ZIOPHARM Oncology.
Which major investors are buying ZIOPHARM Oncology stock?
ZIOP stock was bought by a variety of institutional investors in the last quarter, including BlackRock Inc., Vanguard Group Inc., Nuveen Asset Management LLC, Invesco Ltd., SG Americas Securities LLC, D. E. Shaw & Co. Inc., Renaissance Technologies LLC and Morgan Stanley. Company insiders that have bought ZIOPHARM Oncology stock in the last two years include David M Md Mauney and Laurence James Neil Cooper. View Insider Buying and Selling for ZIOPHARM Oncology.
How do I buy shares of ZIOPHARM Oncology?
Shares of ZIOP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is ZIOPHARM Oncology's stock price today?
One share of ZIOP stock can currently be purchased for approximately $4.59.
How big of a company is ZIOPHARM Oncology?
ZIOPHARM Oncology has a market capitalization of $746.12 million and generates $150,000.00 in revenue each year. The biotechnology company earns $-53,120,000.00 in net income (profit) each year or ($0.48) on an earnings per share basis. ZIOPHARM Oncology employs 48 workers across the globe.View Additional Information About ZIOPHARM Oncology.
What is ZIOPHARM Oncology's official website?
How can I contact ZIOPHARM Oncology?
ZIOPHARM Oncology's mailing address is ONE FIRST AVENUE PARRIS BUILDING 34, BOSTON MA, 02129. The biotechnology company can be reached via phone at 617-259-1970 or via email at [email protected]
MarketBeat Community Rating for ZIOPHARM Oncology (NASDAQ ZIOP)
MarketBeat's community ratings are surveys of what our community members think about ZIOPHARM Oncology and other stocks. Vote "Outperform" if you believe ZIOP will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ZIOP will underperform the S&P 500 over the long term. You may vote once every thirty days.
